James Investment Research Inc. Trims Stock Position in Zoetis Inc. $ZTS

Key Points

• James Investment Research cut its Zoetis stake by 79.1% in Q4, selling 8,793 shares and ending the quarter with 2,329 shares worth $293,000.
• Analyst sentiment is mixed with a consensus rating of "Hold" and an average target of $152.25 (7 Buy, 7 Hold, 1 Sell); Citigroup recently initiated coverage with a Buy and a $145 target.
• Zoetis beat Q4 EPS estimates ($1.48 vs. $1.40), set FY2026 guidance of $7.00–$7.10 EPS, has a market cap of about $49.6B, and pays a $0.53 quarterly dividend (annual $2.12, ~1.8% yield).

James Investment Research Inc. reduced its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 79.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,329 shares of the company's stock after selling 8,793 shares during the quarter. James Investment Research Inc.'s holdings in Zoetis were worth $293,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis during the 4th quarter valued at $25,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis during the 4th quarter valued at $30,000. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Zoetis during the 3rd quarter valued at $31,000. Holos Integrated Wealth LLC bought a new stake in shares of Zoetis during the 4th quarter valued at $32,000. Finally, Board of the Pension Protection Fund bought a new stake in shares of Zoetis during the 4th quarter valued at $38,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Get Zoetis SMS alerts:

Sign Up

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. William Blair restated an "outperform" rating on shares of Zoetis in a report on Monday, March 2nd. Bank of America boosted their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a "neutral" rating in a report on Friday, February 13th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. Weiss Ratings cut shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Finally, Citigroup assumed coverage on shares of Zoetis in a report on Wednesday, April 15th. They set a "buy" rating and a $145.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $152.25.

Zoetis Stock Performance

Shares of Zoetis stock opened at $117.85 on Tuesday. The stock has a market cap of $49.57 billion, a price-to-earnings ratio of 19.58, a PEG ratio of 1.78 and a beta of 0.98. The firm's 50-day moving average is $120.65 and its 200 day moving average is $125.10. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analysts' expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis's revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 7.02 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis's payout ratio is presently 35.22%.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.